Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration
British Journal of Ophthalmology, ISSN: 1468-2079, Vol: 100, Issue: 12, Page: 1629-1633
2016
- 30Citations
- 42Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations30
- Citation Indexes30
- 30
- CrossRef25
- Captures42
- Readers42
- 42
- Mentions1
- News Mentions1
- News1
Most Recent News
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection; Zaltrap
STUDY INFORMATION OFFICIAL TITLE: Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study CURRENT STATUS: Recruiting STUDY TYPE: Interventional SPONSOR AGENCY:Rafic Hariri University HospitalCLASS:Other
Article Description
Purpose In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept. Methods Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept intravitreal injection (1.25mg/0.05mL) from March 2015 to November 2015. Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression and by spectral domain optical coherence tomography were carried out at baseline day 1, 1week, 1month, 2months and 3months after injections. Results 30 eyes were treated (22 Caucasians, 8 Indians; 16 men, 14 women; 14 right eyes and 16 left eyes) with mean age of 74.3years with 11 treatment-naïve cases and 19 having had treatment-non-naïve. Best-corrected visual acuity improved from baseline logMAR 1.08-0.74 at 1week, 0.72 at 1month, 0.67 at 2months and 0.71 at 3months (p<0.001 for all time periods). Central macular thickness in microns decreased from 332.8 to 302.0 at 1week, 244.8 at 1month, 229.0 at 2months and 208.2 at 3months (p<0.001 for all time periods). There were no signs of intraocular inflammation, or change in lens status or increase in intraocular pressure throughout the study. Conclusions Off label use of ziv-aflibercept improves visual acuity, without detectable ocular toxicity and offers a cheaper alternative to the same molecule aflibercept, especially in low/middle-income countries and in countries where aflibercept (Eylea) is not available.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84966312381&origin=inward; http://dx.doi.org/10.1136/bjophthalmol-2015-308319; https://clinicaltrials.gov/ct2/show/NCT02486484; http://www.ncbi.nlm.nih.gov/pubmed/27030277; https://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2015-308319; https://dx.doi.org/10.1136/bjophthalmol-2015-308319; https://bjo.bmj.com/content/100/12/1629
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know